Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Page 1
Defining the natural history of tumefactive demyelination: A retrospective cohort of 257 patients.
Fereidan-Esfahani M, Decker PA, Weigand SD, Lopez Chiriboga AS, Flanagan EP, Tillema JM, Lucchinetti CF, Eckel-Passow JE, Tobin WO. Fereidan-Esfahani M, et al. Among authors: lucchinetti cf. Ann Clin Transl Neurol. 2023 Sep;10(9):1544-1555. doi: 10.1002/acn3.51844. Epub 2023 Jul 13. Ann Clin Transl Neurol. 2023. PMID: 37443413 Free PMC article.

Severe initial attack-related disability (EDSS 4) was more common in patients with motor symptoms (81/143 vs. 35/106, p < 0.0001), encephalopathy (20/143 vs. 2/106, p < 0.0001) and ADC restriction on initial MRI (42/63 vs. 15/33, p = 0.04). Poor long-term outcome (ED

…

Severe initial attack-related disability (EDSS 4) was more common in patients with motor symptoms (81/143 vs. 35/106, p < 0.0001), enceph

…
Long-term clinical, imaging and cognitive outcomes association with MS immunopathology.
Kalinowska-Lyszczarz A, Tillema JM, Tobin WO, Guo Y, Weigand SD, Metz I, Brück W, Lassmann H, Giraldo-Chica M, Port JD, Lucchinetti CF. Kalinowska-Lyszczarz A, et al. Among authors: lucchinetti cf. Ann Clin Transl Neurol. 2023 Mar;10(3):339-352. doi: 10.1002/acn3.51723. Epub 2023 Feb 9. Ann Clin Transl Neurol. 2023. PMID: 36759436 Free PMC article.
INTERPRETATION: In this study, immunopathological heterogeneity of early-active MS lesions identified at biopsy does not correlate with different long-term clinical, neuroimaging or cognitive outcomes. This could be explained by the fact that while active white matter lesi …
INTERPRETATION: In this study, immunopathological heterogeneity of early-active MS lesions identified at biopsy does not correlate with diff …
Clinical Correlation of Multiple Sclerosis Immunopathologic Subtypes.
Tobin WO, Kalinowska-Lyszczarz A, Weigand SD, Guo Y, Tosakulwong N, Parisi JE, Metz I, Frischer JM, Lassmann H, Brück W, Linbo L, Lucchinetti CF. Tobin WO, et al. Among authors: lucchinetti cf. Neurology. 2021 Nov 9;97(19):e1906-e1913. doi: 10.1212/WNL.0000000000012782. Epub 2021 Sep 9. Neurology. 2021. PMID: 34504026 Free PMC article.
Similarly, patients with pattern III pathology were likely to have progressive disease compared to patients with patterns I or II when followed up for 5 years (24% overall, p = 0.49), with no differences in long-term survival, despite a more fulminant attack presentation. …
Similarly, patients with pattern III pathology were likely to have progressive disease compared to patients with patterns I or II when follo …
Long-term clinical, MRI, and cognitive follow-up in a large cohort of pathologically confirmed, predominantly tumefactive multiple sclerosis.
Kalinowska-Lyszczarz A, Tillema JM, Tobin WO, Guo Y, Fitz-Gibbon PD, Weigand SD, Giraldo-Chica M, Port JD, Lucchinetti CF. Kalinowska-Lyszczarz A, et al. Among authors: lucchinetti cf. Mult Scler. 2022 Mar;28(3):441-452. doi: 10.1177/13524585211024162. Epub 2021 Jul 2. Mult Scler. 2022. PMID: 34212755
BACKGROUND: Limited studies have described long-term outcomes in pathology confirmed multiple sclerosis (MS). OBJECTIVES: To describe long-term clinical-radiographic-cognitive outcomes in a prospectively followed cohort of patients with pathologically confirmed CNS …
BACKGROUND: Limited studies have described long-term outcomes in pathology confirmed multiple sclerosis (MS). OBJECTIVES: To describe …
Long-term Outcomes in Patients With Myelin Oligodendrocyte Glycoprotein Immunoglobulin G-Associated Disorder.
Lopez-Chiriboga AS, Sechi E, Buciuc M, Chen JJ, Pittock SJ, Lucchinetti CF, Flanagan EP. Lopez-Chiriboga AS, et al. Among authors: lucchinetti cf. JAMA Neurol. 2020 Dec 1;77(12):1575-1577. doi: 10.1001/jamaneurol.2020.3115. JAMA Neurol. 2020. PMID: 32865549 Free PMC article.
This cohort study reports outcomes of long-term follow-up in patients with myelin oligodendrocyte glycoprotein antibody-associated disorder....
This cohort study reports outcomes of long-term follow-up in patients with myelin oligodendrocyte glycoprotein antibody-associated di …
Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder.
Chen JJ, Flanagan EP, Bhatti MT, Jitprapaikulsan J, Dubey D, Lopez Chiriboga ASS, Fryer JP, Weinshenker BG, McKeon A, Tillema JM, Lennon VA, Lucchinetti CF, Kunchok A, McClelland CM, Lee MS, Bennett JL, Pelak VS, Van Stavern G, Adesina OO, Eggenberger ER, Acierno MD, Wingerchuk DM, Lam BL, Moss H, Beres S, Gilbert AL, Shah V, Armstrong G, Heidary G, Cestari DM, Stiebel-Kalish H, Pittock SJ. Chen JJ, et al. Among authors: lucchinetti cf. Neurology. 2020 Jul 14;95(2):e111-e120. doi: 10.1212/WNL.0000000000009758. Epub 2020 Jun 17. Neurology. 2020. PMID: 32554760 Free PMC article.
The optimal treatment for reducing relapses is unknown. To help determine the efficacy of long-term immunotherapy in preventing relapse in patients with MOGAD, we conducted a multicenter retrospective study to determine the rate of relapses on various treatments. METHODS: …
The optimal treatment for reducing relapses is unknown. To help determine the efficacy of long-term immunotherapy in preventing relap …
Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome.
Chen JJ, Flanagan EP, Jitprapaikulsan J, López-Chiriboga ASS, Fryer JP, Leavitt JA, Weinshenker BG, McKeon A, Tillema JM, Lennon VA, Tobin WO, Keegan BM, Lucchinetti CF, Kantarci OH, McClelland CM, Lee MS, Bennett JL, Pelak VS, Chen Y, VanStavern G, Adesina OO, Eggenberger ER, Acierno MD, Wingerchuk DM, Brazis PW, Sagen J, Pittock SJ. Chen JJ, et al. Among authors: lucchinetti cf. Am J Ophthalmol. 2018 Nov;195:8-15. doi: 10.1016/j.ajo.2018.07.020. Epub 2018 Jul 26. Am J Ophthalmol. 2018. PMID: 30055153 Free PMC article.
Persistent MOG-IgG seropositivity occurred in 61 of 62 (98%). A total of 61% received long-term immunosuppressant therapy. CONCLUSIONS: Manifestations of MOG-IgG-positive optic neuritis are diverse. Despite recurrent attacks with severe vision loss, the majority of patient …
Persistent MOG-IgG seropositivity occurred in 61 of 62 (98%). A total of 61% received long-term immunosuppressant therapy. CONCLUSION …
NEDA treatment target? No evident disease activity as an actionable outcome in practice.
Parks NE, Flanagan EP, Lucchinetti CF, Wingerchuk DM. Parks NE, et al. Among authors: lucchinetti cf. J Neurol Sci. 2017 Dec 15;383:31-34. doi: 10.1016/j.jns.2017.10.015. Epub 2017 Oct 13. J Neurol Sci. 2017. PMID: 29246616 Review.
NEDA has also been proposed as a treatment goal in clinical care. At this point, the long-term implications of early NEDA remain largely unknown. We review current NEDA definitions, use in clinical trials, and its prospects for routine use as an actionable treatment target …
NEDA has also been proposed as a treatment goal in clinical care. At this point, the long-term implications of early NEDA remain larg …
Relapses in multiple sclerosis: Relationship to disability.
Goodin DS, Reder AT, Bermel RA, Cutter GR, Fox RJ, John GR, Lublin FD, Lucchinetti CF, Miller AE, Pelletier D, Racke MK, Trapp BD, Vartanian T, Waubant E. Goodin DS, et al. Among authors: lucchinetti cf. Mult Scler Relat Disord. 2016 Mar;6:10-20. doi: 10.1016/j.msard.2015.09.002. Epub 2015 Sep 8. Mult Scler Relat Disord. 2016. PMID: 27063617 Review.
This review considers in detail the importance of the occurrence of relapses to the ultimate course of MS and the impact of relap setreatment (both acutely and prophylactically) on the long-term outcome for individuals. The ultimate goal of therapy in MS is the reduction o …
This review considers in detail the importance of the occurrence of relapses to the ultimate course of MS and the impact of relap setreatmen …
Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later.
Pittock SJ, Lucchinetti CF. Pittock SJ, et al. Among authors: lucchinetti cf. Ann N Y Acad Sci. 2016 Feb;1366(1):20-39. doi: 10.1111/nyas.12794. Epub 2015 Jun 10. Ann N Y Acad Sci. 2016. PMID: 26096370 Free PMC article. Review.
We also suggest that NMOSDs should now be considered under the umbrella term autoimmune aquaporin-4 channelopathy....
We also suggest that NMOSDs should now be considered under the umbrella term autoimmune aquaporin-4 channelopathy....
13 results